Diabetes insipidus (DI) is a rare medical condition that disrupts the body's ability to regulate water, resulting in excessive thirst and an unusually high volume of urine. This condition affects the kidneys' ability to concentrate urine and causes individuals to produce between 3 and 20 quarts of dilute, colourless urine daily, compared to an average of 1 to 2 quarts. It is pertinent to note that DI is not related to diabetes mellitus, which disrupts the body's insulin production.

Types Of Diabetes Insipidus

This condition results from damage to the hypothalamus or pituitary gland, which impairs the production or release of vasopressin, a hormone responsible for water retention. When vasopressin levels are inadequate, the kidneys fail to conserve water, leading to excessive urination. It can result from Brain injuries or surgeries, tumours, infections or inflammation and aneurysms.

Nephrogenic Diabetes Insipidus

This type occurs when the kidneys fail to respond to vasopressin, causing excessive fluid loss. Common triggers include chronic kidney disease, and electrolyte imbalances, such as high calcium or low potassium levels. Additionally, medications like lithium

and urinary tract blockages can also cause Nephrogenic DI.

Gestational Diabetes Insipidus

A rare condition seen only during pregnancy, this occurs when the placenta produces an enzyme that breaks down vasopressin or increases prostaglandin levels, reducing kidney sensitivity to the hormone. Symptoms of this are usually mild and often resolve postpartum but can recur in future pregnancies.

Symptoms And Warning Signs

• Severe thirst, often leading to the consumption of over a gallon of water daily
• Frequent urination (polyuria), sometimes exceeding 20 quarts per day
• Nighttime urination and bed-wetting
• Weakness, muscle pain, and preference for cold drinks

In severe cases, dehydration may develop, manifesting as fatigue, dizziness, dry mouth, confusion, nausea, or fainting. Infants and children with DI may exhibit crankiness, poor feeding, slow growth, fever, or vomiting.

Causes And Risk Factors

DI stems from issues with vasopressin production or response. Central DI arises from damage to brain structures, while nephrogenic DI relates to kidney dysfunction. Risk factors include:

- Genetic mutations affecting water regulation

- Certain medications like diuretics or lithium

- Metabolic disorders that alter calcium or potassium levels

- Brain injuries or surgeries

Diagnosis And Testing

Diagnosing DI involves a combination of medical history, physical exams, and specialized tests:

- Urinalysis: Evaluates urine concentration and glucose levels to distinguish DI from diabetes mellitus.

- Blood tests: Check electrolyte, glucose, and vasopressin levels.

- Water deprivation test: Measures changes in weight, blood sodium, and urine concentration during fluid restriction.

- MRI: Detects abnormalities in the hypothalamus or pituitary gland.

- Genetic screening: Identifies inherited risk factors.

Although DI is rare, affecting about 1 in 25,000 people, early diagnosis and targeted treatment can significantly improve quality of life. Researchers continue to explore its causes and treatments to better support those living with this challenging condition.

Something as basic as an IV set, syringe, cannula or catheter can make a huge difference in a patient’s essential care and treatment. But a recent FDA survey has raised questions about the affordability of these hospital consumables and whether the lack of transparency in pricing can pose a threat to patient safety.

Maharashtra Food and Drug Administration Commissioner Tukaram Mundhe recently flagged exorbitantly priced hospital consumables and medical devices used in inpatient departments.

The food and drug regulator sought Centre’s intervention to straighten pricing of essential and life-saving medical devices, saying these practices should be ideally “fair, transparent and ethical”.

Maharashtra FDA Chief Tukaram Mundhe Flags Costly Hospital Consumables

The Maharashtra State Price Monitoring Resource Unit, operating under the state FDA, recently conducted the market survey covering medical devices used in inpatient departments, including IV sets, syringes, nebuliser, and oxygen-mask kits, and other consumables.

The survey found that some commonly used medical devices had a gap of up to 2,841% between procurement prices and printed maximum retail prices (MRPs).

For example, an IV infusion set purchased for Rs 11.05 was listed at an MRP of Rs 325. A 10 ml syringe purchased for Rs 6.75 had an MRP of Rs 57.20, while a catheter bought for Rs 29.41 had an MRP of Rs 310.

Maharashtra FDA Commissioner Tukaram Mundhe has sought intervention from the Centre and the National Pharmaceutical Pricing Authority (NPPA), arguing that patients admitted to hospitals are not in the position to bargain over medical products that are essential to their treatment. They may not have the opportunity to compare prices, search for another brand, or simply refuse the product.

In a recent interview, Mundhe said, “A trade margin of 2800 per cent is by any terms not acceptable, either as a consumer or as a hospital or as a regulator.”

Mundhe highlighted this problem in his letter to the Department of Pharmaceuticals, writing, “Because hospitalised patients critically require these non-negotiable surgical consumables during active treatment, they possess zero bargaining power in IPD settings.”

He also described the steep pricing as “completely irrational and unjustified” and argued that the absence of strict statutory price caps for several medical-device categories can leave patients facing large and opaque price differences.

The Centre has now sought a report from the NPPA on the price discrepancies flagged by the Maharashtra FDA.

Also read: Syphilis Among Australian Women Has Risen By 167% In The Last Decade: How It Can Affect Pregnancy & Newborns?

Costly Hospital Consumables May Become A Patient-Safety Issue

World Patient Safety Day is observed on September 17 every year to raise global awareness about the safety of patients and reduce preventable harm in healthcare.

As far as patient safety is concerned, it is not only about whether a device is sterile, functional, or medically appropriate. Affordability and transparency can also influence whether patients are able to access and continue necessary treatment.

A fat hospital bill may cause financial burden, discouraging patients from seeking timely treatment. For families paying out of pocket, unexpected costs can affect decisions about where to seek care, whether to continue treatment or whether to delay non-emergency follow-up.

Mundhe has described the issue directly as a patient-protection concern, saying, “This is not merely a pricing issue; it is a patient-protection issue.”

Also read: Ferritin Face: Can Pale Skin Signal Iron Deficiency?

Industry’s Response To The Maharashtra FDA

The procurement price of a device, however, cannot automatically be treated as the final cost of safely delivering it to a patient.

Hospitals may incur costs related to sterile storage, inventory, staff, emergency availability, wastage, expiry, infrastructure, quality checks, and safe disposal.

Industry representatives have therefore argued that pricing frameworks should distinguish between basic commodity consumables and complex medical technologies.

In a statement, the Association of Healthcare Providers of India (AHPI) said, “Price of device or medicine is very small part of overall cost of administering healthcare, which include manpower (doctors, nurses, paramedical, administration etc.) maintaining infection free environment, infrastructure etc.”

They also reacted to Maharashtra FDA’s pricing concerns and said that hospitals play no part in setting up MRPs of these products.

A new social media trend is prompting people to look more closely at their skin, lips, eyes, hair and nails for possible signs of iron deficiency.

The trend, being referred to as “ferritin face,” centers on an appearance that people describe as looking unusually tired — including dull or dry skin, pale conjunctiva, cracked lips, dark circles under the eyes, and brittle hair and nails.

What Is ‘Ferritin Face’?

“Ferritin face” is not a medical term. Ferritin is a protein that stores and releases iron in the body.

Social media users are increasingly sharing photos of changes in their appearance and linking them to low ferritin or iron deficiency. Some are also encouraging others to get their ferritin levels tested.

“Shout out to the person who commented on one of my videos ... ‘you should get your ferritin levels checked because your lips are very pale,’” one woman said in a TikTok video. “It turns out there’s a reason for why I look so tired and crappy all the time.”

Also read: Bryan Johnson's Autoimmune Gastritis Sheds Light On Iron Deficiency In Americans

Can Iron Deficiency Affect Your Appearance?

Although there is no standard medical definition of “ferritin face,” low iron levels can coincide with visible changes in the face and other parts of the body.

“While the catchy name is a social media invention, the idea that depleted iron can affect how someone looks is medically valid,” Anna Komorowski, division chief of hematology and medical oncology at Northwell's Northern Westchester Hospital in Mount Kisco, New York, was quoted as saying to MedPage Today.

“Importantly, these changes typically occur when deficiency has progressed significantly, not from mildly suboptimal levels.”

Why Iron Deficiency Can Be Missed

Iron deficiency is common, affecting nearly a third of adults in the United States. But it can be difficult to recognize because symptoms may be vague and develop gradually. Iron levels are also not routinely checked.

According to research published in JAMA Network Open, about one in four Americans may have inadequate iron intake or absorption. In the study of more than 8,000 Americans, 14 per cent of adults had absolute iron deficiency, reflecting depleted iron stores.

Even after excluding common causes such as anemia, pregnancy, heart failure and chronic kidney disease, 11 per cent remained iron deficient. Another 15 per cent had functional iron deficiency, where iron levels appear normal but the body cannot use the mineral effectively.

“Because some patients may be iron-deficient without being anemic, they may go on for a very long time without being diagnosed,” Imo Akpan, a hematologist at NewYork-Presbyterian and associate professor of medicine at Columbia University Irving Medical Center, was quoted as saying to the Washington Post.

What Are The Common Signs Of Iron Deficiency?

Iron deficiency can cause a range of symptoms, including:

• Constant tiredness
• Weakness
• Pale skin
• Shortness of breath
• Dizziness
• Headaches
• Hair loss
• Difficulty concentrating
• Frequent infections
• Under-eye circles,
• Cracks at the corners of the mouth,
• Brittle or slower-growing nails
• Exercise intolerance,
• Cold hands and feet,
• Brain fog
• Cravings for non-food items such as ice, soap or chalk.

How Is Iron Deficiency Diagnosed?

Iron deficiency can be assessed with blood tests, including a ferritin test, which measures the body's stored iron. Ferritin levels below 30 nanograms per millilitre can indicate iron deficiency.

How Is Iron Deficiency Managed?

Management depends on the underlying cause and the severity of the deficiency. It can include improving dietary iron intake and taking iron supplements when advised by a healthcare professional.

Iron-rich foods include spinach, beans, lentils, nuts and dates. Vitamin C-rich foods, such as oranges and lemons, can also be included in the diet.

When discussing patient safety in chronic disease management, conversations often focus on drug safety profiles, accurate dosing, and acute complication prevention. In long-term conditions like diabetes, which affects over 100 million people in India, patient safety extends far beyond the medicine. It lies at the intersection of patient education, reliable delivery systems, continuous monitoring, and structured medical guidance.

For instance, the recent evolution in diabetes therapies, such as the shift from 365 daily basal insulin injections a year to just 52 once-weekly administrations, marks a major turning point in chronic care. Reducing injection frequency addresses therapeutic fatigue and needle anxiety, factors that have historically delayed necessary insulin initiation by several years in India. As advanced delivery systems make administration simpler, ensuring that the patient continues long-term treatment is a key requirement for chronic care.

This is where a comprehensive system becomes critical. An advanced delivery device or once-weekly formulation is an enabler. As an intuitive delivery system, it offers accurate dosing and convenience, but cannot interpret fluctuating blood glucose trends, adjust for lifestyle changes, or recognize early warning signs of hypoglycaemia on its own. Long-term patient safety views advanced delivery as an integral link of a broader patient-care framework, which includes:

Also read: Ozempic, Wegovy & PMOS: How GLP-1 Drugs Are Changing PMOS Treatment?

Education as the primary step

Patient safety begins with health literacy. Understanding dose titration, storage conditions, hypoglycaemia protocols, and blood glucose monitoring transforms a patient from a passive recipient into an empowered manager of their health.

Reliability in delivery

Delivery mechanisms, whether daily smart pens or weekly formulations, must deliver predictable, mechanical accuracy. Reliable delivery builds patient confidence, minimizes dosing errors, and alleviates administration anxiety.

Continuous follow-ups

Diabetes is a progressive, dynamic condition. While delivery devices ensure precise administration, continuous engagement with healthcare professionals ensures that treatment regimens adapt to ageing, comorbidities, and lifestyle changes over time. In many cases, technology evolves in response to the pain points shared by the patient.

As the world marks World Patient Safety Day, the focus must expand beyond modernizing treatment delivery to strengthening the entire system surrounding the patient. Innovations in drug delivery are major milestones, but their real-world safety and effectiveness depend entirely on the educational and clinical scaffolding supporting them.

Grounding modern delivery solutions in patient education and clinical continuity creates a model where diabetes care is not only less burdensome, but safe for a lifetime.